CapsoVision, Inc. (CV)
NASDAQ:CV
Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$330.26M
Enterprise Value$307.62M
Total Cash (Recent Filing)$17.93M
Total Debt (Recent Filing)$788.00K
Price to Earnings (P/E)―
Beta-1.47
Next Earnings
Aug 13, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding49,963,585
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue22.68
Enterprise Value/Gross Profit43.90
Enterprise Value/Ebitda-11.54
Forecast
1Y Price Target
$10.50Price Target Upside-20.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$15.80M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Stable Gross MarginsSustained double‑digit top‑line growth alongside mid‑50s gross margins indicates durable product demand and healthy unit economics. This combination supports scalable revenue expansion and gives the company room to invest in commercialization while pursuing operating leverage toward profitability.
Operating Results Improving Toward BreakevenProgression to near‑breakeven operating performance reflects tightened cost structure and improving operating leverage. If sustained, improved EBIT/EBITDA reduces external funding reliance, shortens the path to positive free cash flow, and materially lowers financing and execution risk over the medium term.
Capital Raise And Clinical RefocusThe $14M private placement plus refocus to a second‑generation colon capsule and expanded pivotal study signals strategic prioritization and sufficient near‑term financing to advance a clearer regulatory pathway. Large patient enrollment and planned 510(k) indicate progress that could unlock commercial adoption and reduce prior regulatory uncertainty.
Bears Say
Persistent Cash BurnConsistently large negative operating and free cash flows signal ongoing structural cash burn that outpaces company size. This pattern implies continued dependency on external financing, increases dilution risk for shareholders, and constrains ability to fund R&D or commercialization without further capital raises.
Deep Net Losses And Negative MarginsExtremely large net losses relative to revenue indicate persistent profitability challenges beneath improving operating lines. Such wide negative margins reflect either high fixed costs or costly development/commercial activities and mean the company must materially improve margins or scale revenue significantly to reach sustainable profitability.
Fragile Capital Base And Dilution RiskWhile reported debt is low, prior periods of deeply negative equity reflect accumulated losses and a thin capital buffer. That fragility raises the likelihood of future equity raises or dilutive financings to support operations and trials, which can dilute existing holders and complicate long‑term planning.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $330.26M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 52 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.13.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,963,585 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -11.575%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
126.84%
Trailing 12-Months
Asset Growth
108.43%
Trailing 12-Months
Company Description
CapsoVision, Inc.
CapsoVision, Inc. operates as a medical technology firm, specializing in creating innovative solutions for diagnosing conditions within the gastrointestinal tract. Their offerings encompass cutting-edge capsule endoscopy systems, specifically CapsoCam Plus and CapsoCam Colon, alongside advanced artificial intelligence-driven imaging platforms.
CV Earnings Call
Q1 2026
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$10.50
▼(-20.63% Downside)
Technical Analysis
Ownership Overview
2.95% Insiders
2.57% Mutual Funds
0.02% Other Institutional Investors
90.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---